225Ac-DOTA-J591

Phase I trial results demonstrate CONV01-α combined with 177Lu-PSMA-I&T achieved 29.8-month median overall survival in metastatic castration-resistant prostate cancer patients, doubling VISION trial outcomes.

Relugolix plus radiotherapy demonstrates safety and efficacy for localized and advanced prostate cancer, offering a potential new treatment approach.

Convergent Therapeutics has received its first shipment of Actinium-225 (Ac-225) from Cardinal Health, marking a significant advancement in the supply chain for this critical radioisotope.

Convergent Therapeutics initiates Phase II CONVERGE-01 trial of CONV01-α for metastatic castration-resistant prostate cancer (mCRPC).

A phase 1/2 trial (NCT04886986) is evaluating the safety and efficacy of combining 225Ac-J591 with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer (mCRPC).